CU24070B1 - Composiciones farmacéuticas para el tratamiento de tumores que expresan regf y gangliósidos n-glicolilados gm3 (neugcgm3) - Google Patents
Composiciones farmacéuticas para el tratamiento de tumores que expresan regf y gangliósidos n-glicolilados gm3 (neugcgm3)Info
- Publication number
- CU24070B1 CU24070B1 CU20110245A CU20110245A CU24070B1 CU 24070 B1 CU24070 B1 CU 24070B1 CU 20110245 A CU20110245 A CU 20110245A CU 20110245 A CU20110245 A CU 20110245A CU 24070 B1 CU24070 B1 CU 24070B1
- Authority
- CU
- Cuba
- Prior art keywords
- gangliosids
- neugcgm3
- glycollated
- regf
- treatment
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001104—Epidermal growth factor receptors [EGFR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/001171—Gangliosides, e.g. GM2, GD2 or GD3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
- C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
- C07K16/4266—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (27)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU20110245A CU24070B1 (es) | 2011-12-27 | 2011-12-27 | Composiciones farmacéuticas para el tratamiento de tumores que expresan regf y gangliósidos n-glicolilados gm3 (neugcgm3) |
| UAA201408435A UA111403C2 (uk) | 2011-12-27 | 2012-04-12 | ФАРМАЦЕВТИЧНІ КОМПОЗИЦІЇ ДЛЯ ЛІКУВАННЯ ПУХЛИН, ЕКСПРЕСУЮЧИХ EGFR І N-ГЛІКОЛІЛГАНГЛІОЗИД GM3 (NeuGсGM3) |
| MYPI2014701762A MY185138A (en) | 2011-12-27 | 2012-12-04 | Pharmaceutical compositions for the treatment of tumors expressing egfr and gm3 n-glycolyl ganglioside (neugcgm3) |
| CA2855182A CA2855182C (en) | 2011-12-27 | 2012-12-04 | Pharmaceutical compositions for the treatment of tumours that express egfr and ganglioside n-glycolyl gm3 (neugcgm3) |
| CN201280062315.8A CN103998098B (zh) | 2011-12-27 | 2012-12-04 | 用于治疗表达EGFR和N‑羟乙酰GM3神经节苷脂(NeuGcGM3)的肿瘤的药物组合物 |
| KR1020147017242A KR101703637B1 (ko) | 2011-12-27 | 2012-12-04 | Egfr 및 강글리오시드 n-글리콜릴 gm3 (neugcgm3)를 발현하는 종양의 치료를 위한 약학 조성물 |
| PCT/CU2012/000007 WO2013097834A1 (es) | 2011-12-27 | 2012-12-04 | COMPOSICIONES FARMACEUTICAS PARA EL TRATAMIENTO DE TUMORES QUE EXPRESAN REGF Y GANGLIÓSIDO N-GLICOLIL GM3 (NeuGcGM3) |
| TR2018/16232T TR201816232T4 (tr) | 2011-12-27 | 2012-12-04 | WGFR ve gangliyozid N-glikolil GM3(NeuGcGM3) ifade eden tümörlerin tedavisine yönelik farmasötik bileşimler. |
| BR112014015693-0A BR112014015693B1 (pt) | 2011-12-27 | 2012-12-04 | Composição, e, kit de reagentes |
| EP12806334.4A EP2805747B1 (en) | 2011-12-27 | 2012-12-04 | Pharmaceutical compositions for the treatment of tumours that express wgfr and ganglioside n-glycolyl gm3(neugcgm3) |
| NZ627012A NZ627012B2 (en) | 2011-12-27 | 2012-12-04 | Pharmaceutical compositions for the treatment of tumours that express egfr and ganglioside n-glycolyl gm3 (neugcgm3) |
| EA201491284A EA030346B1 (ru) | 2011-12-27 | 2012-12-04 | Фармацевтические композиции для лечения опухолей, экспрессирующих egfr и n-гликолилганглиозид gm3 (neugcgm3) |
| SG11201403014XA SG11201403014XA (en) | 2011-12-27 | 2012-12-04 | Pharmaceutical compositions for the treatment of tumours that express egfr and ganglioside n-glycolyl gm3 (neugcgm3) |
| AU2012361321A AU2012361321C1 (en) | 2011-12-27 | 2012-12-04 | Pharmaceutical compositions for the treatment of tumours that express EGFR and ganglioside N-glycolyl GM3 (NEUGCGM3) |
| JP2014549356A JP6027137B2 (ja) | 2011-12-27 | 2012-12-04 | Ｅｇｆｒ及びガングリオシドｎ−グリコリルｇｍ３（ｎｅｕｇｃｇｍ３）を発現する腫瘍の治療のための医薬組成物 |
| MX2014007919A MX359476B (es) | 2011-12-27 | 2012-12-04 | Composiciones farmaceuticas para el tratamiento de tumores que expresan regf y gangliósido n-glicolil gm3 (neugcgm3). |
| PE2014001031A PE20142328A1 (es) | 2011-12-27 | 2012-12-04 | Composiciones farmaceuticas para el tratamiento de tumores que expresan regf y gangliosido n-glicolil gm3 (neugcgm3) |
| ES12806334.4T ES2694324T3 (es) | 2011-12-27 | 2012-12-04 | Composiciones farmacéuticas para el tratamiento de tumores que expresan el REGF y el gangliósido N-glicolil GM3 (NeuGcGM3) |
| US14/369,435 US9790279B2 (en) | 2011-12-27 | 2012-12-04 | Pharmaceutical compositions for the treatment of tumors expressing EGFR and GM3 N-glycolyl ganglioside (NeuGcGM3) |
| TW101146617A TWI523663B (zh) | 2011-12-27 | 2012-12-11 | 供治療表現表皮生長因子受體（ＥＧＦＲ）和ＧＭ３ Ｎ－羥乙醯基神經節苷酯（ＮｅｕＧｃＧＭ３）之腫瘤用的醫藥組成物 |
| ARP120105011 AR089490A1 (es) | 2011-12-27 | 2012-12-27 | COMPOSICIONES FARMACEUTICAS PARA EL TRATAMIENTO DE TUMORES QUE EXPRESAN REGF Y GANGLIOSIDO N-GLICOLIL GM3 (NeuGcGM3) |
| TNP2014000203A TN2014000203A1 (en) | 2011-12-27 | 2014-05-06 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF TUMORS EXPRESSING EGFR AND GM3 N- GLYCOLYL GANGLIOSIDE (NeuGcGM3) |
| CL2014001236A CL2014001236A1 (es) | 2011-12-27 | 2014-05-12 | Uso de una composicion que comprende un compuesto contra el receptor de egf y un compuesto contra el gangliosido neugcgm3 para tratar cancer; y kit utilizado que comprende dichos compuestos. |
| PH12014501202A PH12014501202A1 (en) | 2011-12-27 | 2014-05-28 | Pharmaceutical compositions for the treatment of tumors expressing egfr and gm3 n-glycolyl ganglioside (neugcgm3) |
| CO14134694A CO6990729A2 (es) | 2011-12-27 | 2014-06-20 | Composiciones farmacéuticas para el tratamiento de tumores que expresan regf y gangliósido n-glicolil gm3 (neugcgm3) |
| IL233323A IL233323B (en) | 2011-12-27 | 2014-06-23 | Medical preparations for the treatment of tumors expressing egfr and gm3 n-glycolyl ganglioside (neugcgm3) |
| ZA2014/05424A ZA201405424B (en) | 2011-12-27 | 2014-07-23 | Pharmaceutical compositions for the treatment of tumours that express egfr and ganglioside n-glycolyl gm3 (neugcgm3) |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU20110245A CU24070B1 (es) | 2011-12-27 | 2011-12-27 | Composiciones farmacéuticas para el tratamiento de tumores que expresan regf y gangliósidos n-glicolilados gm3 (neugcgm3) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CU20110245A7 CU20110245A7 (es) | 2013-08-29 |
| CU24070B1 true CU24070B1 (es) | 2015-01-29 |
Family
ID=47435671
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU20110245A CU24070B1 (es) | 2011-12-27 | 2011-12-27 | Composiciones farmacéuticas para el tratamiento de tumores que expresan regf y gangliósidos n-glicolilados gm3 (neugcgm3) |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US9790279B2 (es) |
| EP (1) | EP2805747B1 (es) |
| JP (1) | JP6027137B2 (es) |
| KR (1) | KR101703637B1 (es) |
| CN (1) | CN103998098B (es) |
| AR (1) | AR089490A1 (es) |
| AU (1) | AU2012361321C1 (es) |
| BR (1) | BR112014015693B1 (es) |
| CA (1) | CA2855182C (es) |
| CL (1) | CL2014001236A1 (es) |
| CO (1) | CO6990729A2 (es) |
| CU (1) | CU24070B1 (es) |
| EA (1) | EA030346B1 (es) |
| ES (1) | ES2694324T3 (es) |
| IL (1) | IL233323B (es) |
| MX (1) | MX359476B (es) |
| MY (1) | MY185138A (es) |
| PE (1) | PE20142328A1 (es) |
| PH (1) | PH12014501202A1 (es) |
| SG (1) | SG11201403014XA (es) |
| TN (1) | TN2014000203A1 (es) |
| TR (1) | TR201816232T4 (es) |
| TW (1) | TWI523663B (es) |
| UA (1) | UA111403C2 (es) |
| WO (1) | WO2013097834A1 (es) |
| ZA (1) | ZA201405424B (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU20170173A7 (es) * | 2017-12-27 | 2019-11-04 | Ct Inmunologia Molecular | Nano-partículas que contienen el gangliósido gm3 como inmunomoduladoras |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0586002T3 (da) * | 1992-08-18 | 2000-06-19 | Centro Inmunologia Molecular | Monoklonale antistoffer, som genkender epidermisvækstfaktor-receptoren, celler og fremgangsmåder heraf og præparater indeho |
| CN1103404A (zh) * | 1993-03-01 | 1995-06-07 | 分子免疫中心 | 识别表皮生长因子受体的新的单克隆抗体，生产这种抗体的细胞和方法以含有这种抗体的组合物 |
| CU22420A1 (es) * | 1993-12-29 | 1996-01-31 | Centro Inmunologia Molecular | Composicion vacunal para el desarrollo de una respuesta contra gangliosidos n glicolilados y su uso para el tratamiento del cancer |
| CU22731A1 (es) | 1998-02-05 | 2002-02-28 | Centro Inmunologia Molecular | Anticuerpo monoclonal que reconoce el oligosacárido ácido siálico n´glicolilado-galactosa-glucosa (ngcneu-gal-glu) en tumores malignos y composiciones farmacéuticas que los contienen |
| PE20020572A1 (es) * | 2000-12-06 | 2002-07-31 | Centro Inmunologia Molecular | Preparaciones para potenciar la inmunogenicidad de antigenos poco inmunogenicos |
| CU23007A1 (es) * | 2001-04-06 | 2004-12-17 | Ct De Inmunologia Molecular Ct De Inmunologia Mole | Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos |
| CU23403A1 (es) * | 2003-04-23 | 2009-08-04 | Centro Inmunologia Molecular | Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores |
-
2011
- 2011-12-27 CU CU20110245A patent/CU24070B1/es active IP Right Grant
-
2012
- 2012-04-12 UA UAA201408435A patent/UA111403C2/uk unknown
- 2012-12-04 JP JP2014549356A patent/JP6027137B2/ja active Active
- 2012-12-04 AU AU2012361321A patent/AU2012361321C1/en active Active
- 2012-12-04 CA CA2855182A patent/CA2855182C/en active Active
- 2012-12-04 US US14/369,435 patent/US9790279B2/en active Active
- 2012-12-04 TR TR2018/16232T patent/TR201816232T4/tr unknown
- 2012-12-04 CN CN201280062315.8A patent/CN103998098B/zh active Active
- 2012-12-04 EP EP12806334.4A patent/EP2805747B1/en active Active
- 2012-12-04 MX MX2014007919A patent/MX359476B/es active IP Right Grant
- 2012-12-04 MY MYPI2014701762A patent/MY185138A/en unknown
- 2012-12-04 ES ES12806334.4T patent/ES2694324T3/es active Active
- 2012-12-04 KR KR1020147017242A patent/KR101703637B1/ko active IP Right Grant
- 2012-12-04 EA EA201491284A patent/EA030346B1/ru not_active IP Right Cessation
- 2012-12-04 SG SG11201403014XA patent/SG11201403014XA/en unknown
- 2012-12-04 BR BR112014015693-0A patent/BR112014015693B1/pt active IP Right Grant
- 2012-12-04 PE PE2014001031A patent/PE20142328A1/es not_active Application Discontinuation
- 2012-12-04 WO PCT/CU2012/000007 patent/WO2013097834A1/es active Application Filing
- 2012-12-11 TW TW101146617A patent/TWI523663B/zh active
- 2012-12-27 AR ARP120105011 patent/AR089490A1/es unknown
-
2014
- 2014-05-06 TN TNP2014000203A patent/TN2014000203A1/en unknown
- 2014-05-12 CL CL2014001236A patent/CL2014001236A1/es unknown
- 2014-05-28 PH PH12014501202A patent/PH12014501202A1/en unknown
- 2014-06-20 CO CO14134694A patent/CO6990729A2/es unknown
- 2014-06-23 IL IL233323A patent/IL233323B/en active IP Right Grant
- 2014-07-23 ZA ZA2014/05424A patent/ZA201405424B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2015000177A1 (es) | Composición para el tratamiento de la hiperlipidemia que comprende un derivado de oxintomodulina | |
| BR112012018947A2 (pt) | composição farmacêutica para tratamento e\ou prevenção do cancêr | |
| CO7061081A2 (es) | Derivados macrocíclicos para el tratamiento de enfermedades | |
| PT2818482T (pt) | Composição farmacêutica para o tratamento de cancro | |
| DK2694038T3 (da) | Farmaceutisk sammensætning | |
| HUE045461T2 (hu) | Gyógyászati készítmény rák kezelésére | |
| BR112014029674A2 (pt) | composto, composição farmacêutica, método para o tratamento de uma doença, utilização de um composto, conjunto para o tratamento de uma condição mediada pela quinase pim e invenção | |
| DK2818481T3 (da) | Farmaceutisk sammensætning til behandling og/eller forebyggelse af cancer | |
| ES2972387T3 (es) | Composiciones farmacéuticas que comprenden ésteres de sorbitán | |
| BR112013033072A2 (pt) | agente para indução de apoptose e composição farmacêutica | |
| BR112013014644A2 (pt) | composição farmacêutica e complexo | |
| BR112014006291A2 (pt) | composição e utilização da composição | |
| BR112014016389A2 (pt) | composições e métodos para o tratamento de doenças e distúrbios hepáticos | |
| BR112015006512A2 (pt) | composição para tratar tecidos biológicos danificados | |
| DK2897594T3 (da) | Farmaceutisk sammensætning | |
| CO6801718A2 (es) | Composición terapéutica para el tratamiento de glioblastoma | |
| BR112014022694A2 (pt) | novos métodos e composições para o tratamento de doença | |
| CU24163B1 (es) | Composición farmacéutica oftalmológica tópica que contiene regorafenib | |
| BR112013030370A2 (pt) | compostos de quinona para tratamento de doenças mediadas por ape1 | |
| BR112014004416A2 (pt) | composições e métodos para o tratamento de doenças neurodegenerativas | |
| DK3466437T3 (da) | Middel til forebyggelse eller terapi af perinatale sygdomme for drøvtyggere | |
| CO7010828A2 (es) | Preparación farmacéutica que comprende ßciclodextrina sustituida | |
| BR112014026326A2 (pt) | composição para tratamento de distúrbios metabólicos | |
| BR112013028890A2 (pt) | composições e métodos para o tratamento de câncer | |
| BR112014031785A2 (pt) | composto, composição farmacêutica, utilização do composto, método para o tratamento do câncer e invenção |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant of patent |